Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

View Full Profile. Learn about our Editorial Policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...

RNA interference, or RNAi, is all the rage these days. According to the Web of Science database (ISI, Philadelphia), the number of articles on the topic jumped from nine in 1998 to 229 in 2002. Why ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...

Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences introduces a novel ...

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...